Extended Data Fig. 6: In vivo efficacy of IL-2α-bias with or without depletion of CD4+T, CD8 +T and NK cells. | Nature Cancer

Extended Data Fig. 6: In vivo efficacy of IL-2α-bias with or without depletion of CD4+T, CD8 +T and NK cells.

From: IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells

Extended Data Fig. 6

(a) Individual tumor growth curves in each treatment group (related to Fig. 3e). (b) Tumor weight measured at the end of study. (c) Body weight change curves. (d) Representative dot plots showing the cell depletion efficiency in tumors. (e) Frequency of CD8+T, CD4+T, Treg and NK cells in CD45+ cells in tumors (top) and blood (bottom). N = 7 mice per group. Mean + s.e.m. is presented, and p-values are calculated using one-way ANOVA for bar graphs in B and E (Dunnett’s multiple comparisons test).

Source data

Back to article page